Literature DB >> 20810098

Intramuscular 17α-hydroxyprogesterone caproate administration attenuates immunoresponsiveness of maternal peripheral blood mononuclear cells.

Lisa M Foglia1, Danielle L Ippolito, Jonathan D Stallings, Craig M Zelig, Peter G Napolitano.   

Abstract

OBJECTIVE: 17α-hydroxyprogesterone caproate (17P) may decrease risk of prematurity by suppressing maternal immunity. We hypothesized that in vivo 17P treatment attenuates immunoresponsiveness of peripheral blood mononuclear cells (PBMCs). STUDY
DESIGN: Study subjects were gravidas receiving weekly prophylactic intramuscular 17P injections. Peripheral blood samples were obtained at 21-27 weeks' gestation. Gestational age-matched, drug-naïve gravidas served as controls. To simulate infection, isolated PBMCs were stimulated with lipoteichoic acid (LTA) or lipopolysaccharide (LPS). Extracellular interleukin-6 (IL-6) concentrations were quantified by an enzyme-linked immunosorbent assay.
RESULTS: Unstimulated IL-6 levels were comparable in PBMCs derived from drug-naïve and 17P-treated subjects. LPS and LTA induced a dose-dependent elevation of IL-6 in control PBMCs. In patients who received exogenous 17P, LPS, and LTA stimulated induction of IL-6 was significantly decreased compared with controls (P = .005 and P = .02).
CONCLUSION: In vivo 17P attenuated immunoreactivity of PBMCs in our in vitro model of Gram-positive and Gram-negative bacterial infection. Published by Mosby, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20810098     DOI: 10.1016/j.ajog.2010.07.016

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

Review 1.  17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.

Authors:  Emma D Deeks
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

2.  Progesterone supplementation and the prevention of preterm birth.

Authors:  Errol R Norwitz; Aaron B Caughey
Journal:  Rev Obstet Gynecol       Date:  2011

3.  Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.

Authors:  Steve N Caritis; Shringi Sharma; Raman Venkataramanan; Dwight J Rouse; Alan M Peaceman; Anthony Sciscione; Catherine Y Spong; Michael W Varner; Fergal D Malone; Jay D Iams; Brian M Mercer; John M Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan Ramin; Margaret Harper
Journal:  Am J Obstet Gynecol       Date:  2011-03-22       Impact factor: 8.661

Review 4.  Progesterone interactions with the cervix: translational implications for term and preterm birth.

Authors:  Bryan Larsen; Joseph Hwang
Journal:  Infect Dis Obstet Gynecol       Date:  2011-10-27

5.  17α-Hydroxyprogesterone Caproate Inhibits Cytokine Production via Suppression of NF-κB Activation.

Authors:  Tao Hu; Chengjifu Tang; Sydney Stern; Luan Yang; Tom Du
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.